NO20083509L - Krystallinske former av (3R,4R)-4-amino-1-[[4-[(3-metoxyfenyl)amino]pyrrolo[2,1-F][1,2,4]triazin-5-yl]metol]piperidin-3-ol - Google Patents

Krystallinske former av (3R,4R)-4-amino-1-[[4-[(3-metoxyfenyl)amino]pyrrolo[2,1-F][1,2,4]triazin-5-yl]metol]piperidin-3-ol

Info

Publication number
NO20083509L
NO20083509L NO20083509A NO20083509A NO20083509L NO 20083509 L NO20083509 L NO 20083509L NO 20083509 A NO20083509 A NO 20083509A NO 20083509 A NO20083509 A NO 20083509A NO 20083509 L NO20083509 L NO 20083509L
Authority
NO
Norway
Prior art keywords
amino
triazin
pyrrolo
piperidin
methoxyphenyl
Prior art date
Application number
NO20083509A
Other languages
English (en)
Inventor
Chenkou Wei
Derrick J Norris
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20083509L publication Critical patent/NO20083509L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Krystallinske former av (3R,4R)-4-amino-1-[[4-[(3-metoksyfenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]metyl]piperidin-3-ol med formelen (I) er tilveiebragt. Også tilveiebragt er et farmasøytisk preparat som omfatter én eller flere krystallinske former av (3R,4R)-4-amino-1-[[4-[(3-metoksyfenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]metyl]piperidin-3-ol, samt en fremgangsmåte for bruk av én eller flere krystallinske former av (3R,4R)-4-amino-1-[[4-[(3-metoksyfenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]metyl]piperidin-3-ol ved behandling av kreft og andre proliferative sykdommer.
NO20083509A 2006-02-16 2008-08-13 Krystallinske former av (3R,4R)-4-amino-1-[[4-[(3-metoxyfenyl)amino]pyrrolo[2,1-F][1,2,4]triazin-5-yl]metol]piperidin-3-ol NO20083509L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77392306P 2006-02-16 2006-02-16
PCT/US2007/062276 WO2007095632A1 (en) 2006-02-16 2007-02-16 Crystalline forms of (3r,4r)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methol]piperidin-3-ol

Publications (1)

Publication Number Publication Date
NO20083509L true NO20083509L (no) 2008-08-29

Family

ID=38093387

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083509A NO20083509L (no) 2006-02-16 2008-08-13 Krystallinske former av (3R,4R)-4-amino-1-[[4-[(3-metoxyfenyl)amino]pyrrolo[2,1-F][1,2,4]triazin-5-yl]metol]piperidin-3-ol

Country Status (8)

Country Link
US (1) US8063208B2 (no)
EP (1) EP1989207B1 (no)
JP (1) JP2009527491A (no)
CN (1) CN101384600B (no)
AT (1) ATE527263T1 (no)
ES (1) ES2372315T3 (no)
NO (1) NO20083509L (no)
WO (1) WO2007095632A1 (no)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201035100A (en) 2008-12-19 2010-10-01 Cephalon Inc Pyrrolotriazines as ALK and JAK2 inhibitors

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2163399A1 (en) 1994-11-24 1996-05-25 Katsuhiro Kawano Triazine derivative, chymase activity inhibitor and nitric oxide production inhibitor
AU735401B2 (en) 1996-08-28 2001-07-05 Pfizer Inc. Substituted 6,5-hetero-bicyclic derivatives
DK1183033T3 (da) 1999-05-21 2006-06-06 Bristol Myers Squibb Co Pyrrolotriazininhibitorer af kinaser
WO2001014378A1 (fr) 1999-08-23 2001-03-01 Shionogi & Co., Ltd. DERIVES DE PYRROLOTRIAZINE A ACTIVITES INHIBANT sPLA¿2?
US6670357B2 (en) 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
JP2004522713A (ja) 2000-11-17 2004-07-29 ブリストル−マイヤーズ　スクイブ　カンパニー ｐ３８キナーゼ関連疾患の処置方法およびキナーゼインヒビターとして有用なピロロトリアジン化合物
US6867300B2 (en) 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
TW200300350A (en) 2001-11-14 2003-06-01 Bristol Myers Squibb Co C-5 modified indazolylpyrrolotriazines
JP2005529890A (ja) * 2002-04-23 2005-10-06 ブリストル−マイヤーズ　スクイブ　カンパニー キナーゼ阻害剤として有用なアリールケトンピロロトリアジン化合物
RS92004A (en) 2002-04-23 2006-12-15 Bristol-Myers Squibb Company Pyrrolo-triazine aniline compounds useful as kinase inhibitors
TW200407143A (en) 2002-05-21 2004-05-16 Bristol Myers Squibb Co Pyrrolotriazinone compounds and their use to treat diseases
TWI272271B (en) 2002-07-19 2007-02-01 Bristol Myers Squibb Co Process for preparing certain pyrrolotriazine compounds
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
WO2004013145A1 (en) 2002-08-02 2004-02-12 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
TW200420565A (en) 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines
US7102001B2 (en) 2003-12-12 2006-09-05 Bristol-Myers Squibb Company Process for preparing pyrrolotriazine
US7064203B2 (en) 2003-12-29 2006-06-20 Bristol Myers Squibb Company Di-substituted pyrrolotriazine compounds
MY145634A (en) * 2003-12-29 2012-03-15 Bristol Myers Squibb Co Pyrrolotriazine compounds as kinase inhibitors
US7102002B2 (en) 2004-06-16 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7102003B2 (en) 2004-07-01 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine compounds

Also Published As

Publication number Publication date
EP1989207B1 (en) 2011-10-05
CN101384600B (zh) 2012-07-11
JP2009527491A (ja) 2009-07-30
ES2372315T3 (es) 2012-01-18
EP1989207A1 (en) 2008-11-12
US8063208B2 (en) 2011-11-22
ATE527263T1 (de) 2011-10-15
US20070191375A1 (en) 2007-08-16
CN101384600A (zh) 2009-03-11
WO2007095632A1 (en) 2007-08-23

Similar Documents

Publication Publication Date Title
EP2114925B8 (en) Azetidine analogues of nucleosidase and phosphorylase inhibitors
NO2017019I2 (no) Enzalutamid eller et farmasøytisk akseptabelt salt derav
ATE482213T1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
AU2005253776A8 (en) Screening methods using c-Abl, Fyn and Syk in combination with tau protein
IL184898A0 (en) Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
DE602006021776D1 (de) Als kinaseinhibitoren geeignete aminopyrimidine
IL184403A0 (en) Method and composition for treating mammalian diseases and injuries caused by the over expression of peroxynitrite
TW200607803A (en) Pyrrole inhibitors of erk protein kinase, synthesis thereof and intermediates thereto
MY147393A (en) Administration of dipeptidyl peptidase inhibitors
ATE497961T1 (de) Als proteinkinaseinhibitoren geeignete verbindungen
ATE451376T1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
WO2006004833A3 (en) Pyrrolotriazine kinase inhibitors
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
DE602007007985D1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine
ATE526328T1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine
WO2007059008A3 (en) N-substituted indenoisoquinolines and syntheses thereof
MY161991A (en) Proteasome inhibitors
TW200633980A (en) Pyridones useful as inhibitors of kinases
DE602005025655D1 (de) Als proteinkinaseinhibitoren geeignete diaminotriazolverbindungen
HK1123733A1 (en) Viral hepatitis treatment
WO2007033266A3 (en) Dipeptidyl peptidase inhibitors for treating diabetis
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
TW200716589A (en) Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]-oxepino [4,5-c] pyrrole
DE602005023877D1 (de) Verfahren zur herstellung von 7-alpha-alkylierte 19-norsteroide

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application
FC2A Withdrawal, rejection or dismissal of laid open patent application